These results may mean that many women with HR+/HER2- breast cancer, the most common subtype, could safely avoid chemotherapy, reducing their financial burden as well as exposure to treatments that may have significant side effects [2–5]. This evidence concerns the gene ERBB2 and breast carcinoma.